CD20-negative pyothorax-associated B cell lymphoma

Acta Haematol. 2005;113(2):144-5. doi: 10.1159/000083453.

Abstract

We describe an 86-year-old male who developed CD20-negative pyothorax-associated B cell lymphoma 64 years after he had suffered from tuberculous pleuritis. Therapy with 8 courses of THP-COP at 2-week intervals was followed by involved-field radiotherapy of 30 Gy. Uncertain complete remission was achieved. Thereafter, local recurrence of pyothorax-associated lymphoma (PAL) at the primary site was seen. The patient received salvage radiotherapy of 50 Gy. The patient died of pneumonia during a second uncertain complete remission. The progression-free survival and overall survival of this patient were 10 and 15 months, respectively. When compared with the median survival of 9 months reported in the literature, the adverse effect of CD20 negativity on prognosis may not apply to PAL patients with an occasional aberrant phenotype.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antigens, CD20
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / analogs & derivatives
  • Doxorubicin / therapeutic use
  • Empyema, Tuberculous / complications*
  • Fatal Outcome
  • Humans
  • Lymphoma, B-Cell / etiology*
  • Lymphoma, B-Cell / therapy
  • Male
  • Pneumonia / etiology
  • Prednisolone / therapeutic use
  • Prognosis
  • Recurrence
  • Remission Induction
  • Salvage Therapy
  • Vincristine / therapeutic use

Substances

  • Antigens, CD20
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisolone

Supplementary concepts

  • VEP-THP protocol